In February 2022, leaders in the treatment of genitourinary malignancies gathered for the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium for presentations and discussions of the latest practice-changing research. Closely following the symposium, CancerNetwork? hosted a game show-style production called 2-Minute Drill, where a live, in-studio moderator posed rapid-fire questions about the meeting to key thought leaders to gauge their outlook on high-level topics. The experts were Alan Haruo Bryce, MD, chair, Division of He-matology/Oncology, Department of Medicine, May Clinic, Phoenix, Arizona; Tanya Dorff, MD, section chief, Genitourinary Disease Program, and associate professor, Department of Medical Oncology Therapeutics Research, City of Hope, Duarte, California; Benjamin H. Lowentritt, MD, director of Minimally Invasive Surgery and Robotics and the Prostate Cancer Care Program, Chesapeake Urology, Towson, Maryland; and Daniel P. Petrylak, MD, professor of medicine (medical oncology) and urology and coleader of the Cancer Signaling Networks, Yale Cancer Center, New Haven, Connecticut.
展开▼
